Introduction
============

Colorectal cancer (CRC) is one of the most commonly diagnosed cancers worldwide. Indeed, most recent data show that CRC is the second leading cause of cancer death, with over 500,000 deaths annually.[@b1-cmar-11-1985]

Hypermutation is characterized by mismatch repair (MMR) deficiency or POLE/ POLD1 driver mutations, indicating a high mutational rate. Accumulating evidence confirms that hypermutation occurs in many cancer types, such as melanoma,[@b2-cmar-11-1985] lung cancer,[@b3-cmar-11-1985] and bladder cancer.[@b4-cmar-11-1985]

Acquisition of genomic instability is a crucial feature of CRC development, and the microsatellite instability (MSI) pathway, which in involved in 15%[@b5-cmar-11-1985],[@b6-cmar-11-1985] of CRC pathogeneses, is known to arise from inactivation of one of four MMR genes: *MSH2, MLH1, MSH6*, and *PMS2*.[@b7-cmar-11-1985]--[@b10-cmar-11-1985] An aberrant MMR process leads to additive mutations throughout the genome and ultimately a "hypermutator" phenotype.[@b10-cmar-11-1985],[@b11-cmar-11-1985] The results of a recent large-scale sequencing analysis also suggest that hypermutation in CRC should not be underestimated.[@b12-cmar-11-1985] Moreover, hypermutation is associated with a predicted high neo-epitope load, which can be exploited for immunotherapy in selected patients who experience conventional therapy failure.[@b13-cmar-11-1985]

Because hypermutated CRC differs from CRC with regard to tumorigenesis, prognosis, and treatment, it is unreasonable to use the same prognostic biomarkers as employed for patients without hypermutations. Here, we propose a prognostic prediction signature for patients with hypermutated CRC. This signature can determine the hypermutated status of tumors and distinguish between patients who have a high or low risk of disease-related death and predict those who are likely to benefit from immunotherapy.

Materials and methods
=====================

Sample collection and DNA extraction
------------------------------------

Fresh tissues were flash frozen in liquid nitrogen after surgery and stored at −80°C until genomic DNA isolation. Only samples from patients with a pathologic diagnosis of CRC were evaluated, but samples were excluded if they contained \<40% tumor cells. Tumor-and matched normal mucosa-derived DNA was purified using the QIAamp DNA mini kit (Qiagen NV, Venlo, The Netherlands).

All patients signed a consent form when the frozen tissue was obtained. This consent form authorized us to conduct scientific research and publish the results anonymously with the approval of the Institutional Review Board (IRB). All protocols and procedures of this study were approved under The Second Affiliated Hospital, School of Medicine of Zhejiang University IRB protocol 2013-042. This study was conducted in accordance with the Declaration of Helsinki.

DNA sequencing and MSI status detection
---------------------------------------

Panel sequencing was performed using a custom-designed panel utilizing Agilent SureSelect capture kit technology (Agilent Technologies, Santa Clara, CA, USA), targeting the exonic region of 524 genes ([Table S1](#SD2-cmar-11-1985){ref-type="supplementary-material"}), with HiSeq 2000 (Illumina, San Diego, CA, USA). Sequence reads were aligned to the human genome (GRCh37/hg19), and unique pairs were used for variant calling. Candidate variants and indels were detected using GATK. Somatic mutations and indels were then identified using MuTect and Strelka, respectively. These variants were annotated with ANNOVAR (Openbioinformatics, USA).[@b14-cmar-11-1985] MSI status was detected using mSINGS.[@b15-cmar-11-1985]

Detection of hypermutated samples and candidate gene screening
--------------------------------------------------------------

The threshold of hypermutation was higher than 10 Mut/ Mb, which was determined according to a recently published large-scale analysis.[@b12-cmar-11-1985] As there are hundreds of mutated genes in a hypermutated tumor, it is impractical to use a mutation frequency ≥5% as a filtering criterion, which will include most of the genes sequenced. Therefore, we employed multiple strategies to screen for candidate prognostic genes in hypermutated CRC. First, we employed a univariate Cox proportional hazard (PH) model to evaluate the association between gene mutations and overall survival (OS) for each gene. Dedicator of cytokinesis 2 (*DOCK2*) was the only gene significantly associated with OS. Second, *POLE* driver mutation and MSI statuses were selected as candidates because replication repair mutations and MSI are observed in most types of hypermutated cancer. We identified *POLE* driver mutations based on the results of Campbell et al.[@b12-cmar-11-1985] However, POLD1 was not included because no driver mutations were found in the present study. Third, activin A receptor type 2A (*ACVR2A*) and *BRAF* were included according to previous studies. *APC, TP53*, and *KRAS*, which have an overall higher mutation frequency in CRC, were also included. Thus, we obtained eight candidate factors (*DOCK2, ACVR2A, BRAF, APC, TP53, KRAS, POLE*, and MSI status) to construct a prognostic model. We summarize the selection process in [Figure 1](#f1-cmar-11-1985){ref-type="fig"}.

Compound score calculation and high-risk patient detection
----------------------------------------------------------

The final follow-up date was October 1, 2016 for patients from The Second Affiliated Hospital, School of Medicine of Zhejiang University (the ZJU cohort) and August 20, 2015 for patients from The Cancer Genome Atlas (TCGA) cohort. Only patients with \>24 months of follow-up survival data were used for the prognosis-related analysis. OS was measured in months from the date of surgery to the date that the patient died. Stage was assessed according to the seventh version of the American Joint Commission on Cancer guidelines.

The compound score was calculated based on the sum of candidate gene mutations for each patient using a Cox PH model. Patients with higher-than-median scores were segregated as the high-risk group; others were defined as the low-risk group. The Cox PH model was employed to evaluate the association between the mutation signature and the clinical endpoint. To rule out over-fitting of the model, MSI data, somatic mutation data, and clinicopathological information for the TCGA cohort were obtained from the TCGA project data portal (<http://www.cbioportal.org>) on July 3, 2017.[@b16-cmar-11-1985] These patients were used as an independent cohort for verification of the significance between the panel and OS.

Statistical analyses
--------------------

Kaplan--Meier survival curve analysis with the log-rank test was applied to estimate the mutation signature in relation to OS. Fisher's exact test, Student's *t*-test, and the Mann--Whitney *U*-test were used to determine differences in clinicopathological variables between subgroups (high-risk vs low-risk/mutant vs wild-type). Multivariate Cox regression was performed to determine the contribution of the mutation signature to survival, adjusting for age, sex, and stage; the Wald test was employed in this analysis. Clinical subgroups of training and testing cohorts were also used to verify the prognostic prediction of the panel. Harrell's concordance index (C-index) was used to quantify predictive accuracies. In addition, multiple permutation tests were performed on both cohorts. To obtain a sufficient sample size for clinical subclass analysis, we pooled the two cohorts and utilized 5-fold cross-validation. All statistical analyses were two-sided. A *P*-value of \<0.05 was considered statistically significant. All analyses were performed using Python 3.6.0 (<https://www.python.org/>) and R 3.4.0 (<https://www.r-project.org/>).

Results
=======

Patients' basic characteristics
-------------------------------

We sequenced 338 samples in our center, from which we identified 45 (13.30%) hypermutated patients as the training data set to construct the prognostic mutation signature. The proportion of hypermutation obtained in this study coincides with that of a previous report. Samples that met the criteria (63 patients) of hypermutation were selected from the TCGA project data portal for an independent testing data set. The demographics of the two initial cohorts, with a total of 108 patients, are shown in [Table S2](#SD3-cmar-11-1985){ref-type="supplementary-material"}. Due to the lack of information on specific staging, location, and survival data in the TCGA data set, 24 patients from TGCA were ultimately selected as the testing group for prognosis analysis. The baseline characteristics of the two groups are presented in [Table 1](#t1-cmar-11-1985){ref-type="table"}.

Identified potential genes for constructing the signature
---------------------------------------------------------

According to the three procedures described above, *DOCK2* was found to be the only gene significantly associated with OS in both the ZJU and TCGA cohorts (HR =1.73, *P*=0.007 and HR =2.08, *P*=0.001, respectively). Combining the remaining selected genes, *DOCK2, ACVR2A, BRAF, APC, TP53, KRAS*, and *POLE* as well as MSI status were chosen as candidate factors for constructing the prognostic signature.

To determine the minimum number of genes able to discriminate outcomes, we began training in the ZJU cohort and stopped increasing the size of the signature when we obtained the maximal C-index. We next constructed a risk classifier based on four genes (*DOCK2, ACVR2A, APC*, and *POLE*), with good concordance (C-index =0.748). We further used multiple permutation testing to confirm the robustness of this signature, which indicated that our signature was not generated by coincidence ([Figure 2](#f2-cmar-11-1985){ref-type="fig"}).

Construction of a 4-gene signature for high-risk hypermutated CRC patients
--------------------------------------------------------------------------

We divided patients into two groups by calculating the compound score for four genes. The compound score was generated from the ZJU cohort and further calculated for each patient in the TCGA cohort. Patients with higher-than-median scores were segregated as the high-risk group, and others were defined as the low-risk group. Patients with a high-risk classifier in the ZJU (HR =10.19, 95% CI: 1.25-- 83.23, *P*=0.007) and TCGA (HR =8.62, 95% CI: 1.87--39.67, *P*=0.001) cohorts had significantly worse survival.

Due to the limited number of patients exhibiting hypermutation (n=45 in ZJU and n=24 in TCGA), we pooled the two cohorts to display the results and perform further subgroup analysis. A high-risk classifier was significantly associated with poor survival (HR =8.83, 95% CI: 2.00--39.04, *P*=0.001; [Figure 3](#f3-cmar-11-1985){ref-type="fig"}).

We also employed a multivariate Cox regression analysis including our 4-gene risk classifier, age, sex, and stage to reveal that the 4-gene risk classifier can serve as an independent determinant of OS in patients with hypermutated CRC (adjusted HR =9.85, 95% CI: 2.07--46.81, *P*=0.004) ([Table 2](#t2-cmar-11-1985){ref-type="table"}). There was no statistically significant difference in the proportion of patients receiving adjuvant chemotherapy between the high-risk and low-risk groups (*P*=0.457, [Table S3](#SD4-cmar-11-1985){ref-type="supplementary-material"}).

The 4-gene signature is powerful in specific subgroups
------------------------------------------------------

We first employed the 4-gene signature for subgroup analysis of stage II and III colon cancer patients, accounting for 74% (78/105) of all included patients. Twenty-two patients were in the high-risk group and twenty-eight in the low-risk group according to the compound score. Because the high-risk patients shared a higher death risk, the results suggested that our 4-gene signature is a powerful prognostic tool for this subgroup (HR =10.91, 95% CI: 1.36--87.50, *P*=0.005; [Figure 4A](#f4-cmar-11-1985){ref-type="fig"}).

As hypermutations are more likely to occur on the right side of colon cancer,[@b14-cmar-11-1985] we selected right-side colon cancer patients and employed the 4-gene signature to predict outcomes. The results showed markedly worse survival among patients in the high-risk group (HR =8.88, 95% CI: 1.06--74.50, *P*=0.015; [Figure 4B](#f4-cmar-11-1985){ref-type="fig"}).

MSI status is important for both prognosis and therapy choice among patients with hypermutated tumors. Thus, we segregated patients into MSI and microsatellite stable (MSS) subgroups, and the results showed that our signature can well predict outcomes in the MSI group (HR =12.57, 95% CI: 1.57--100.69, *P*=0.002; [Figure 4C](#f4-cmar-11-1985){ref-type="fig"}), although the difference was not significant in the MSS group (*P*=0.082).

Comparison of prognostic biomarkers in hypermutated CRC
-------------------------------------------------------

We established a prognostic predictor based on four genes (*DOCK2, ACVR2A, APC*, and *POLE*) for hypermutated CRC. Previous studies have also proposed prognostic risk stratifications based on MSI/POLE or MSI/BRAF. Hypermutation, MSI status, and tumor mutational burden (TMB) are correlated with the response to immune checkpoint inhibitors, and we therefore conducted a performance comparison for these risk factors/groups using the pooled cohort.

Our 4-gene risk classifier stratifies patients with hypermutated CRC into high-risk and low-risk groups. Worse outcomes were significantly associated with the high-risk group. MSI/POLE status divided patients into three groups: POLE, MSI, and POLE/MSI. Although the MSI group accounted for the majority of patients, with better survival than those of the POLE group (75% vs 40%, 5-year survival rate), the difference was not significant ([Figure S1A](#SD1-cmar-11-1985){ref-type="supplementary-material"}). No death occurred in two patients in the POLE/MSI group. MSI/BRAF status also classified patients into three groups, MSI, MSS/ BRAF-wild-type, and MSS/BRAF-p.V600E, and there was no prognostic difference between the first two groups, with only one patient in the last group ([Figure S1B](#SD1-cmar-11-1985){ref-type="supplementary-material"}). To investigate the association between TMB and prognosis, we divided patients into high-TMB and low-TMB groups based on the median (40 mut/Mb). High-TMB patients showed a worse, but not significant, outcome ([Figure S1C](#SD1-cmar-11-1985){ref-type="supplementary-material"}). All patients with a POLE driver mutation were sorted into the high-TMB group, which was confirmed by the poor prognosis of the POLE group. Lastly, consistent with the results of the multivariate Cox regression analysis, TNM staging confirmed that the prognosis of hypermutated CRC does not comply with the TNM staging system ([Figure S1D](#SD1-cmar-11-1985){ref-type="supplementary-material"}).

Discussion
==========

In our study, patients with hypermutated CRC comprised 13.30%, which agrees with previous TCGA studies (in which hypermutated CRC accounted for 15.6%,[@b16-cmar-11-1985] 16.9%,[@b17-cmar-11-1985] and 15%).[@b18-cmar-11-1985] To predict the prognosis of hypermutated CRC, we constructed a prognostic mutation signature of four genes (*DOCK2, ACVR2A, APC,* and *POLE*) that separated patients into two risk groups. The high-risk group was significantly associated with worse survival (HR =8.62, *P*=0.001). Overall, the proportion of hypermutated CRC suggested that hypermutation should not be underestimated in CRC. Furthermore, this special subgroup of CRC patients deserves greater attention because there are currently many novel therapeutic options. For example, Campbell et al[@b12-cmar-11-1985] recently reported dramatically different survival rates among 217 patients with hypermutated cancer. In addition, the abundance of immune checkpoint inhibitors that target programmed cell death 1 (PD-1) or their ligands (PD-L1) brings new hope to hypermutated tumor patients. Many studies have proven that hypermutation and MSI status predict the clinical benefit of immune checkpoint inhibitors, which can lead to durable remission in some patients with conventional therapy failure.[@b19-cmar-11-1985],[@b20-cmar-11-1985] Thus, establishing a prognostic biomarker will help physicians screen patients who have poor prognoses but good responses to immunotherapy. Regardless, not only are the clinicopathological features of hypermutated tumors poorly understood, but prognostic tools are also lacking due to a lack of understanding of this type of disease. Recently, sequencing of individual cancer genomes has prompted scientists to search for biomarkers based on gene mutation signatures. However, most previous efforts treated hypermutation and non-hypermutation as a whole or focused on non-hypermutated CRC.[@b21-cmar-11-1985] To the best of our knowledge, no well-known study has been conducted on hypermutated CRC, highlighting the value of our work.

The genes in our signature include *DOCK2, ACVR2A, APC*, and *POLE*. *APC* and *POLE* play important roles in the development and progression of CRC, and *DOCK2* and *ACVR2A* are worth discussing further. *DOCK2* is a gene frequently mutated in CRC and esophageal cancer,[@b22-cmar-11-1985] and data for the pooled cohort showed that *DOCK2* is more frequently mutated in hypermutated CRC (38.0%) than in non-hypermutated CRC (3.9%). Germline deficiency of *DOCK2* leads to life threatening, invasive bacterial and viral infections,[@b23-cmar-11-1985],[@b24-cmar-11-1985] and transgenic mice experiments confirmed that *DOCK2* is required for recruitment and infiltration of immune cells into the colon mucosa during bacterial infection.[@b24-cmar-11-1985],[@b25-cmar-11-1985] Several recent studies have reported that the gut microbiome influences the efficacy of anti-PD-1/L1 immunotherapy.[@b26-cmar-11-1985],[@b27-cmar-11-1985] Accordingly, *DOCK2* may participate in the immune response initiated by gut microbes, and its deficiency is most likely involved in an immune evasion mechanism of high-risk hypermutated CRC. *ACVR2A* has two 8-bp polyadenine tracts, a hot spot for mutation in MSI CRC.[@b28-cmar-11-1985],[@b29-cmar-11-1985] *ACVR2A* is a member of the TGF-β superfamily, which plays a key role during CRC progression, and a previous study showed that *ACVR2A* is the most frequently mutated gene of hypermutated CRC. Further study of *ACVR2A* is urgently needed.

We performed subgroup analysis to verify the universality of our 4-gene signature. Due to the different treatment strategies and clinical outcomes in colon and rectal cancer, stage II and III colon cancer patients were selected as the first subgroup, and the results showed that our signature is sufficiently powerful in this subgroup. Nonetheless, the effectiveness of our 4-gene signature in rectal cancer needs to be further investigated. We then focused on the subgroup of high microsatellite instability (MSI-H) patients because these CRC patients are considered to have different clinical outcomes and therapeutic choices; for example, patients with MSI-H CRC usually do not respond to 5-fluorouracil chemotherapy, unlike non-hypermutated CRC patients. We further classified MSI-H patients into two risk groups using our 4-gene signature and observed that the low-risk group showed markedly good survival. Although recent studies have reported that MSI-H patients have a good response to immune checkpoint inhibitors, there are still some patients for whom benefit may not actually be gained or for whom the response may not be translated to OS. Using our 4-gene signature in MSI patients to identify different risk groups is promising in clinical practice that selecting patients who will actually gain benefits from immunotherapy, with an effect on OS. The final subgroup analysis focused on the primary locations, as hypermutation is more common in right-side colon cancer.[@b16-cmar-11-1985] This subgroup analysis further verified that our 4-gene signature is a powerful tool for patients with hypermutated CRC.

Using gene mutation status to construct a prognostic signature is currently a hot topic in cancer research. A powerful prognostic signature will identify different risk group of patients to receive different intensity of therapies. Our 4-gene signature classifies hypermutation CRC patients into two groups and we suggest that high-risk group patients should receive more aggressive treatments than the low-risk group patients. A previous study stratified patients into three groups based on the MSI/BRAF status: MSI/BRAF-wild-type or mutant (best prognosis), MSS/BRAF-wild-type (intermediate prognosis), and MSS/BRAF mutant (worst prognosis).[@b30-cmar-11-1985] Although the MSI/BRAF status can as a whole serve as a prognostic biomarker for CRC, it was not suitable for hypermutated CRC according to our study. TMB has also been recommended as a critical criterion correlated with the objective response rate of anti-PD-1/L1 immunotherapy. However, the threshold in different kinds of tumor remains controversial, and the power for predicting patient prognosis needs to be developed. Compared with the above biomarkers, our 4-gene risk classifier exhibits good performance for predicting clinical outcome in patients with hypermutated CRC.

However, there are some limitations to our study; the most important one is the limited number of patients in our study group due to the small percentage of hypermutated CRC. Fortunately, gene sequencing technology is gradually maturing and becoming faster and less expensive. We will continue to collect cases of hypermutated CRC to further verify our signature. Furthermore, although we believe that the 4-gene signature is promising in selecting patients who will gain benefits from immunotherapy, its significant value still needs to be verified in prospective studies that we are devoting ourselves to.

Conclusion
==========

We constructed a 4-gene signature for patients with hypermutated CRC, which can classify patients into different risk groups and predict prognosis. This signature is a powerful tool in stage II and III colon cancer and MSI-H CRC. Future prospective studies are needed to confirm the power of the 4-gene signature in patients receiving immunotherapy.

Supplementary material
======================

###### 

Power of different prognosis biomarkers.

**Notes:** (**A**) MSI/POLE status divides patients into three groups: POLE, MSI, and POLE/MSI. The difference of patients' survival is not significant. (**B**) MSI/BRAF status divides patients into three groups: MSI, MSS/BRAF-wild-type, and MSS/BRAF-V600E. The difference of patients' survival is not significant. (**C**) Patients were divided into high TMB and low TMB groups by median(as 40 mut/Mb). The difference of patients' survival is not significant. (**D**) Hypermutated patients were not comply the traditional TNM stages.

**Abbreviations:** MSI, microsatellite instability; MSS, microsatellite stable; TMB, tumor mutational burden.

###### 

List of 524 genes for panel sequencing

  ---------- ------------ ---------- ---------- --------- --------- ----------- ---------- --------- ---------- -------- ---------- ----------- --------------------------------------------------- --------- ---------
  ABCA13     ASPM         C20orf54   COL6A3     EIF3E     FAT4      HEMGN       LCORL      MSH2      NOLC1      PLD5     QSER1      SCN9A       ST8SIA6                                             TRAK2     ZFP36L2
  ABCA6      ATAD5        C2orf44    COL6A6     EIF4A2    FBN2      HIST1H2BC   LEKR1      MSH3      NOTCH1     PLXNC1   RABGGTB    SEC63       STAG1                                               TRIM49B   ZFPM1
  ABCA8      ATM          C9         CRB1       ELF3      FBXW7     HIST1H2BM   LGR5       MSH6      NOTCH2     PMS1     RAD21      SEMA3D      STK11                                               TRNT1     ZFPM2
  ABCA9      ATP10A       CA4        CRTC1      ELMO1     FCRL1     HIVEP2      LIFR       MTOR      NPIPB5     PMS2     RAD50      SERPINF1    STK31                                               TSGA10    ZNF208
  ABCB1      ATP1A2       CACNA1B    CSF2RA     ELMOD2    FETUB     HLA-B       LIG1       MTUS1     NRAS       POLD1    RAD51AP2   SHKBP1      STON1-GTF2A1L                                       TSHZ3     ZNF233
  ACOX2      ATP1B2       CASP8      CSMD1      EP300     FLG       HMCN1       LIG4       MTUS2     NTHL1      POLD3    RALGAPA1   SI          STPG2                                               TSPO2     ZNF267
  ACSL6      ATP8A2       CBL        CSMD3      EPCAM     FLG2      HNRNPL      LMNA       MUC1      NTSR2      POLE     RALY       SLC12A1     SUFU                                                TUSC3     ZNF285
  ACTC1      ATR          CCDC141    CTNNB1     ERBB2     FLI1      HRNR        LPHN3      MUC12     NUDT11     POLE2    RASA1      SLC13A1     SYCP1                                               UACA      ZNF334
  ACVR1B     ATXN1        CCDC168    CTNND2     ERBB4     FOXA1     HSPA8       LRIF1      MUC16     NUP107     POLE4    RASSF2     SLC25A51    SYNE1                                               UBE4A     ZNF382
  ACVR2A     AUTS2        CCDC62     CTSA       ERCC1     FOXE1     HYDIN       LRP1B      MUC17     NUP50      POLN     RB1        SLC30A8     SYT16                                               UBN1      ZNF417
  ADAM21     AXIN1        CCDC66     CUX1       ERCC5     FREM2     IDO2        LRP2       MUC4      OPRD1      POLQ     RBM12      SLC4A10     TBC1D7                                              UBR5      ZNF469
  ADAM29     AXIN2        CCDC73     DCAF6      ERCC6     FRG1      IGSF3       LRRC4C     MUC6      OR11H12    POSTN    RBMX       SLC5A10     [Table 1](#t1-cmar-11-1985){ref-type="table"} XR1   UGT2A2    ZNF479
  ADAM7      AZGP1        CCDC88A    DCHS2      ERICH3    FRY       IL15        LRRD1      MUTYH     PABPC1     POTEC    RBMXL3     SLCO1B1     TBP                                                 UGT3A2    ZNF521
  ADAMTS12   B2M          CCNE1      DDX6       EXO1      FSHR      IRF5        LRRIQ1     MYCBP2    PAFAH1B2   POTEE    REV3L      SLCO6A1     TCF7L2                                              UNC13C    ZNF569
  ADAMTS20   B3GNT6       CD40LG     DEFB108B   EYS       FSIP2     ITLN2       LRRK2      MYCN      PARP1      POTEH    RFC1       SLITRK1     TDRD3                                               UNC5CL    ZNF600
  ADCY2      B3GNT9       CD44       DNAH11     F10       FSTL5     ITPR1       LRRN3      MYO16     PARP4      POTEJ    RGS17      SLITRK4     TDRD6                                               UNC93A    ZNF665
  ADM2       BAGE3        CD58       DNAH14     F13B      GABRG3    IVL         LRRTM3     MYO3B     PAX1       PPM1E    RGS22      SLX4        TEAD2                                               USH2A     ZNF671
  AGBL2      BAI3         CD7        DNAH3      F5        GALNT12   JAK2        MAGEB3     MYO9A     PBRM1      PRDM9    RHCG       SMAD2       TELO2                                               UTP23     ZNF679
  AKT1       BAIAP2L2     CDC42EP1   DNAH5      FAM123B   GGT1      KCNJ5       MAGEL2     MYOCD     PCBP1      PREX2    RHOA       SMAD3       TG                                                  UTS2B     ZNF727
  ALPK2      BAP1         CDH1       DNAH6      FAM135B   GLI3      KCNN3       MAL2       MYPOP     PCDH9      PRKAA1   RIMS2      SMAD4       TGFBR2                                              VN1R2     ZNF728
  ALS2CR11   BAX          CDKN2A     DNAH7      FAM153B   GLT8D2    KCNS2       MANSC4     NAALAD2   PCDHB15    PRKRIR   RIN3       SNTG2       TGIF1                                               VPS37B    ZNF729
  ALS2CR12   BCL9         CFAP58     DNAH8      FAM184A   GLTPD2    KCNT2       MAP1B      NALCN     PCGF6      PRSS35   RMI1       SORBS2      TLR4                                                VTI1A     ZNF735
  ALX4       BCL9L        CHEK2      DNAJC24    FAM194B   GNAT2     KDM6A       MAP2K1     NBEA      PCLO       PSCA     RNF43      SOX2        TLR7                                                WBSCR17   ZNF750
  AMPD1      BIVM-ERCC5   CLEC18B    DOCK10     FAM71E2   GNG12     KIAA0408    MAP2K4     NBPF15    PCSK7      PSG5     ROBO2      SOX9        TM6SF1                                              WDR11     ZNF761
  ANKRD12    BLM          CLUL1      DOCK2      FAN1      GOLGA4    KIF4B       MAP3K19    NBPF3     PHF2       PTCH1    RP1        SPARCL1     TMEM173                                             XIRP2     ZNF787
  ANKRD30A   BMPR1A       CMYA5      DPP10      FANCA     GOLGB1    KIRREL      MAPK1      NEB       PIEZO2     PTEN     RPA4       SPATA31D1   TMEM184A                                            XKR9      ZNF804A
  APC        BMPR2        CNBD1      DPY19L2    FANCD2    GPN1      KMT2B       MAPK8IP1   NEFH      PIK3CA     PTPLA    RPL22      SPDYE6      TMPRSS13                                            XPC       ZNF804B
  APOBEC3B   BRAF         CNTN1      DSEL       FANCE     GPR112    KRAS        MDM2       NFE2L2    PIK3R1     PTPN11   RPS20      SPG20       TNNI3K                                              XRCC1     ZNF831
  APOBEC3F   BRCA1        CNTN6      DUX4       FANCI     GPR149    KRTAP10-6   MFRP       NIN       PIK3R3     PTPRK    RSPO2      SPIDR       TOP2B                                               ZBED9     ZNF850
  ARHGAP15   BRCA2        CNTNAP5    DYNC2H1    FANCM     GREM1     KRTAP4-5    MKI67      NKX2-1    PKD2L2     PTPRT    RSPO3      SPP1        TOP3B                                               ZDBF2     
  ARHGAP32   BRIP1        COL11A1    EBLN1      FAT1      GRIA2     KRTAP5-5    MLH1       NLRP14    PLCE1      PTPRZ1   RYR2       SPTA1       TOPAZ1                                              ZFC3H1    
  ARHGEF12   C17orf70     COL12A1    EDNRB      FAT2      GRIN2A    KTN1        MLH3       NME8      PLCL1      PYHIN1   SACS       SPZ1        TP53                                                ZFHX4     
  ARID1A     C1ORF74      COL18A1    EFHB       FAT3      HDGFRP2   LCA5        MNX1       NMI       PLCZ1      QRFPR    SCN1A      SSBP1       TPM3                                                ZFP28     
  ---------- ------------ ---------- ---------- --------- --------- ----------- ---------- --------- ---------- -------- ---------- ----------- --------------------------------------------------- --------- ---------

###### 

Baseline values of all initial selected patients

                                   ZJU center(n=45)   TCGA (n=63)   *P*-value
  -------------------------------- ------------------ ------------- -----------
  Age, years, mean ± SD            60.00±2.10         66.02±1.94    0.459
  Median OS, months, mean ± SD     67.97±4.30         40.73±4.73    0.413
  Sex, female, n (%)               16 (35.56)         25 (39.68)    0.663
  Mutation burden, mb, mean ± SD   73.62±12.08        46.40±5.14    0.000
  Stage, n (%)                                                      0.519
   I                               4 (8.89)           11 (17.46)    
   II                              27 (60.00)         35 (55.55)    
   III                             13 (28.89)         13 (20.63)    
   IV                              1 (2.22)           2 (3.17)      
  Location, n (%)                                                   0.003
   Right-side colon                22 (48.89)         50 (79.37)    
   Left-side colon                 14 (31.11)         7 (11.11)     
   Rectum                          9 (20.00)          5 (7.94)      
  MSI-H, n (%)                     22 (48.89)         39 (61.90)    0.179
  POLE driver mutant, n (%)        9 (20.00)          5 (7.94)      0.066
  ACVR2A mutant, n (%)             34 (75.55)         18 (23.57)    0.000
  APC mutant, n (%)                28 (62.22)         27 (42.86)    0.152
  DOCK2 mutant, n (%)              20 (44.44)         42 (33.33)    0.284

**Abbreviations:** OS, overall survival; MSI-H, high microsatellite instability; TCGA, The Cancer Genome Atlas; ZJU, Zhejiang University.

###### 

Chemotherapy of patients in the final analysis

                        High group(n=33)   Low-risk group(n=35)   *P*-value
  --------------------- ------------------ ---------------------- -----------
  Chemotherapy, n (%)   18 (54.55)         14 (40.00)             0.457
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###### 

Characteristics of included patients

                                   ZJU center(n=45)   TCGA (n=24)   *P*-value
  -------------------------------- ------------------ ------------- -----------
  Age, years, mean ± SD            60.00±2.10         70.04±2.87    0.168
  Median OS, months, mean ± SD     67.97±4.30         42.32±5.76    0.410
  Sex, female, n (%)               16 (35.56)         11 (45.83)    0.405
  Mutation burden, mb, mean ± SD   73.62±12.08        43.01±7.67    0.344
  Stage, n (%)                                                      0.411
   I                               4 (8.89)           5 (20.83)     
   II                              27 (60.00)         12 (50.00)    
   III                             13 (28.89)         5 (20.83)     
   IV                              1 (2.22)           0 (0.00)      
  Location, n (%)                                                   0.025
   Right-side colon                22 (48.89)         19 (79.17)    
   Left-side colon                 14 (31.11)         3 (12.50)     
   Rectum                          9 (20.00)          1 (4.17)      
  MSI-H, n (%)                     22 (48.89)         21 (87.50)    0.002
  POLE driver mutant, n (%)        9 (20.00)          1 (4.17)      0.075
  ACVR2A mutant, n (%)             34 (75.55)         7 (29.17)     0.002
  APC mutant, n (%)                28 (62.22)         7 (29.17)     0.312
  DOCK2 mutant, n (%)              20 (44.44)         7 (29.17)     0.278

**Abbreviations:** OS, overall survival; MSI-H, high microsatellite instability; TCGA, The Cancer Genome Atlas; ZJU, Zhejiang University.

###### 

Multivariate Cox regression analysis of 4-gene signature

                        HR (95% CI)          *P*-value
  --------------------- -------------------- -----------
  4-Gene risk model     9.85 (2.07--46.81)   0.004
  Age                   1.02 (0.98--1.06)    0.442
  Sex, female vs male   2.49 (0.82--7.56)    0.108
  Stage                 0.65 (0.28--1.49)    0.307

**Notes:** Multivariate Cox regression analysis was performed on 67 of 69 pooled patients who met the criteria of having \>24 months follow-up survival data, as well as age, sex, and stage information. *P*-value was calculated by Wald test.
